Straits Times Index
3,077.16 -6.92 (-0.22%) S&P 500
4,574.89 +5.11 (+0.11%) Dow
36,132.56 -71.88 (-0.20%) Nasdaq
14,272.40 +86.91 (+0.61%) Bitcoin USD
42,282.27 +961.46 (+2.33%) CMC Crypto 200
866.74 +6.19 (+0.72%)
ADTX Jan 2024 5.000 put
| Previous close | 4.6000 |
| Open | 4.6000 |
| Bid | 4.5000 |
| Ask | 7.5000 |
| Strike | 5.00 |
| Expiry date | 2024-01-19 |
| Day's range | 4.6000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 856 |
- Business Wire
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
MOUNTAIN VIEW, Calif., October 05, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. T
Business WireAditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
RICHMOND, Va. & MOUNTAIN VIEW, Calif., September 08, 2023--Aditxt,® Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel
- Business Wire
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va., September 06, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) an
